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Abstract 
Background 
The relationship between body mass index (BMI) (weight (kg)/ height(m2)) and serious non-
AIDS events is not well understood. 
Methods 
We followed D:A:D study participants on antiretroviral therapy from their first BMI 
measurement to the first occurrence of the endpoint or end of follow-up (N=41,149 followed for 
295,147 person-years). The endpoints were cardiovascular disease (CVD); diabetes; non-AIDS-
defining cancers (NADCs) and BMI-NADCs (cancers known to be associated with BMI in 
general population); and all-cause mortality. Using poisson regression models, we analysed BMI 
as time-updated, lagged by 1 year, and categorized at: 18.5, 23, 25, 27.5 and 30 kg/m2. 
Results 
Participants were largely male (73%) with the mean age of 40 years (SD 9.7) and baseline 
median BMI of 23.3 (IQR: 21.2-25.7). Overall, BMI showed a statistically significant J-shaped 
relationship with the risk of all outcomes except diabetes. The relative risk (RR) for the BMI of 
<18.5 and >30 (95% CI) compared to 23-25, respectively, was as follows: CVD: 1.46(1.15-1.84) 
and 1.31(1.03-1.67); NADCs: 1.78(1.39-2.28) and 1.17(0.88-1.54); ‘BMI-NADCs’: 1.29(0.66-
2.55) and 1.92(1.10-3.36). For all-cause mortality, there was an interaction by gender (P<0.001): 
RR in males: 2.47(2.12-2.89) and 1.21(0.97-1.50); and in females: 1.60(1.30-1.98) and 
1.02(0.74-1.42). RR remained around 1 for intermediate categories of BMI. The risk of diabetes 
linearly increased with increasing BMI (P<0.001).  
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Conclusions 
Risk of CVD, a range of cancers, and all-cause mortality increased at low BMI (<18.5) and then 
tended to increase only at BMI>30 with a relatively low risk at BMI of 23-25 and 25-30. High 
BMI was also associated with risk of diabetes. 
Key words: HIV; Obesity; BMI; AIDS; non-AIDS; all-cause mortality 
 
INTRODUCTION 
Excess weight is now increasingly prevalent in HIV-positive individuals receiving antiretroviral 
therapy (ART).1,2 While body mass index, BMI (measured as weight (kg)/height (m2)) is an 
anthropometric measure and does not directly measure total body fat or biological markers of 
disease, it remains an easy and low-cost metric to screen for risk of certain conditions.3 However, 
in HIV-positive individuals, the relationship between BMI and various serious non-AIDS events 
(SNAEs) is not well studied. 
In the general population, increasing BMI is associated with increased risk of various clinical 
outcomes including cardiovascular disease (CVD)3, diabetes mellitus (DM), several cancers such 
as those of gastrointestinal tract and endometrium,4 and all-cause mortality.5 Also, very low BMI 
has been associated with increased risk of mortality.5  
HIV-positive individuals are unique in that they are exposed to ongoing inflammation/immune 
activation, ART toxicities, higher prevalence of life-style risk factors such as smoking and a 
higher overall risk of various SNAEs than general population.6 Further, BMI in this group is 
itself associated with immunosuppression and certain antiretroviral drugs among other factors.2 
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In one large cohort study BMI correlated strongly with CD4 count response to ART regardless of 
baseline CD4 count, with a highest CD4 count response at BMI levels of 25-30 but worse at 
higher or lower levels.7 On the other hand, weight gain following ART initiation has been shown 
to be harmful to cardio-metabolic health, especially in those with ‘normal/overweight’ weight at 
baseline.8 It is therefore possible that being HIV-infected modifies the relationship between BMI 
and various outcomes in this population. However, limited, if any, studies have rigorously 
evaluated BMI as a risk factor for non-AIDS outcomes.9 Better understanding of how BMI 
relates to SNAEs in HIV-positive individuals is therefore needed. This information will provide 
the key data to clinicians and the HIV community regarding the health implications of BMI-a 
well-known, easily and economically measured potential risk factor. 
In this paper, we analysed the data from the Data Collection on Adverse Events of Anti-HIV 
Drugs (D:A:D) study, a large heterogeneous cohort with well-validated outcomes and available 
data on a wide range of risk factors, to assess the relationship between latest BMI and the 
subsequent risk of various SNAEs and all-cause mortality. 
 
METHODS 
Study population and follow-up 
The design of the D:A:D study has been described in detail elsewhere.10 In brief, it is an 
observational study of >49,000 HIV-positive people from 11 cohorts from Europe, Australia, and 
the USA. All participants were under active follow-up in their cohorts at the time of enrolment in 
the study. The primary study aim was to investigate the associations between use of ART and 
major non-AIDS events and death. Data are collected prospectively during routine clinic visits; 
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the standardized data set includes information on demographic factors, AIDS-related events, 
known risk factors for CVD, laboratory markers for monitoring HIV infection and CVD, and 
ART. Clinical events are regularly monitored and endpoints are centrally adjudicated.  
In this study, we included all participants in the D:A:D cohort who had initiated ART, had at 
least one BMI measure available and at least one year of further follow-up from study entry. 
Follow-up commenced from the later of cohort enrolment or ART initiation or first BMI 
measurement. Non-AIDS cancers were collected systematically from 2004 and were therefore 
analyzed from 1st Jan 2004 onwards. Follow-up ended on the first occurrence of the respective 
endpoint or was censored at death or, 1st February 2014 or six months after last follow-up visit. 
All individuals had no pre-existing diagnoses of CVD, diabetes mellitus (DM) or non-AIDS 
cancers (NADCs) at study initiation. 
Endpoints  
The endpoints of interest were: (i) first CVD event, defined as the composite of myocardial 
infarction (MI), sudden cardiac death or invasive cardiovascular procedure (coronary artery 
bypass graft, carotid endarterectomy or angioplasty), or confirmed stroke; (ii) DM, defined as 
fasting glucose > 7.0 mmol/L on at least two occasions or a single value of NGSP haemoglobin 
A1c > 6.5%, or symptoms with a random glucose > 11.1 mmol/L, or 2-h oral glucose tolerance 
test > 11.1 mmol/L, or use of antidiabetic drugs (see www.chip.dk for details); (iii) NADCs 
(other than basal or squamous cell skin cancer, pre-cancers, and relapses); (iv) ‘BMI-related 
NADCs’- a composite outcome of cancers thought to be associated with BMI in the general 
population (i.e. malignancies of oesophagus, pancreas, colon and rectum, breast, endometrium, 
kidney, thyroid and gallbladder)4,11; and finally (v) All-cause mortality. 
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Statistical methods 
BMI was the main exposure factor analysed as a time-updated variable lagged by 1-year (i.e. 
there was at least 1-year time-gap between last BMI measurement and the endpoint, so as to 
minimize bias from reverse causation) and categorised at the following clinical cut-offs: 18.5, 23, 
25, 27.5 and 30 kg/m2. The choice of strata was driven by the broad WHO BMI clinical cut-offs 
(underweight (<18.5), normal (18.5-25), overweight (25-30) and obese (>30))3, with additional 
cut-offs at 23 and 27.5 to better define the relationship. In sensitivity analyses, we also 
categorized BMI in deciles. 
We used Poisson regression to model the relationship between BMI and each endpoint. Models 
were adjusted for key confounders not thought to be on the causal pathway for each respective 
endpoint. Potential confounders were identified using directed acyclic graphs (DAGs).12 All 
variables, including age and CD4 count, were analyzed as time-updated (lagged by 1-year) 
where possible. In case a time-updated variable was not recorded at a given visit, previous 
known value was carried forward. A missing variable category was created for all variables to 
ensure all observations were included in models. 
For CVD we adjusted for race (White/ Black/ Other/Unknown), sex, mode of transmission (sex 
between men/ injecting drug use/ sex between men and women/ other), family history of CVD, 
age, smoking status (current/ past/ never/ unknown), current abacavir use, cumulative protease 
inhibitor (PI) and nucleoside reverse transcriptase inhibitor (NRTI) use in years, and CD4 count 
(categorized as ≤200, 201-350, >350 cells/mm3). For CVD outcome, we also present analysis 
from models additionally adjusted for variables thought to be on a causal pathway as identified 
in DAGs.  These include lipids (total, HDL and LDL cholesterol), systolic blood pressure (SBP) 
and incident DM.  
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Similarly models for DM, NADC and all-cause mortality were adjusted for respective 
confounders (listed at the bottom of Figure-1 in ‘Results’). Models for all outcomes were 
additionally adjusted for calendar year and clinical cohort. Finally, we also checked for 
interaction between BMI and sex for all outcomes. 
The following sensitivity analyses were performed: (i) We categorized BMI according to the 
deciles of the distribution to allow for the more detailed examination of the relationship between 
BMI and outcomes; (ii) We lagged the BMI and all other time-updated variables by 2 years 
instead of one year and also analysed first measured BMI (‘baseline’ BMI) (to further minimize 
bias from reverse causation); (ii) and for the CVD and mortality outcomes, models were 
additionally adjusted for calculated creatinine clearance using the Cockcroft-Gault formula as 
decreased renal function has been associated with these outcomes.13,14 Since data on serum 
creatinine and weight were not available for a couple of cohorts, we only analysed these 
variables in sensitivity analysis. 
All analyses were performed using STATA version 14 (STATA Corporation, College Station 
TX, USA). 
 
RESULTS 
Participant characteristics 
A total of 41,149 individuals with 295,147 person-years of follow-up (PYFU) for the all-cause 
mortality outcome were included. PYFU varied for each outcome depending on follow-up time. 
Participants were largely male (73%) with baseline mean age of 40 years and median (IQR) BMI 
of 23.3 (21.2- 25.7).  Table-1 shows key characteristics by baseline BMI category. Prevalence of 
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smoking and injecting drug use as mode of transmission appeared to be inversely related to the 
baseline BMI category, while mean total cholesterol and systolic blood pressure tended to 
positively correlate with BMI. During follow-up, BMI was measured at the median (IQR) of 6 
months (4-9 months) interval. For all key confounders (including smoking, lipid levels, systolic 
blood pressure, hepatitis B and C status) a vast majority (≥85%) of individuals had data recorded 
at least at some point during the follow-up. About 15% of individuals had unknown smoking 
status throughout the follow-up.  
BMI and risk of SNAEs 
Table-2 shows the number of people experiencing each outcome, and the incidence rates per 
1000 PYFU. Figure 1 (panels a-d) shows incidence rate ratios (IRR or relative risk) from various 
models for all outcomes by time-updated BMI category. The BMI category of 23-25 was chosen 
as the reference category based on rates shown in Table-2. Overall BMI was a significant 
predictor for all outcomes (overall P<0.05 for the BMI variable in all models). The relationship 
of BMI was J or U-shaped with the risk of all SNAEs except DM as detailed below. Also, the 
effect of BMI on all-cause mortality tended to vary by sex (P for interaction between BMI and 
sex for all-cause mortality: <0.001) as shown in Table-2 (incidence rates) and Figure 1d (relative 
risks), but not for all other outcomes. 
There were 1398 CVD events (rate: 4.8/1000 PYFU). Compared to those with a BMI of 23-25, 
IRR (95% CI) for those with a BMI of ≤18.5 was 1.46 (1.15 to 1.84), for 18.5-23 was 1.10 (0.96 
to 1.27) and for >30, it was 1.31 (1.03 to 1.67), in the models adjusted for known confounders. 
Further adjustment for variables known to be on the causal pathway between BMI and CVD 
(such as SBP, and lipids) attenuated the relative risk at levels >30 but not at BMI levels ≤18.5 or 
18.5-23 (Fig 1a).     
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For DM, the relationship with BMI was linear, i.e. increasing risk with increasing BMI, with 
relative risk nearly 3.5 times (IRR 3.39, 95% CI: 2.79 to 4.12) for BMI>30 vs BMI of 23-25 (Fig 
1b). 
There were 1143 NADCs at a rate of 3.9/1000 PYFU of which 184 (rate: 0.6/1000 PYFU) were 
BMI-cancers. The IRR (95% CI) for NADC was highest for those with a BMI of ≤18.5: 1.78 
(1.39 to 2.28) and for those with a BMI of 18.5-23: 1.30 (1.11-1.53) and tended to be higher 
among those with a BMI>30 although the 95% CI crossed 1 (1.17, 0.88 to 1.54). However, for 
the BMI-cancers, BMI >30 was associated with nearly twice the risk compared to BMI 23-25 
(IRR 1.90, 1.11 to 1.36) (Fig 1c). 
Finally, the rates and IRR (95% CI) of all-cause mortality varied by sex. For males, the J-shaped 
relationship with BMI was more prominent. For males with a BMI of ≤18.5, the relative risk of 
mortality was about 2.5 times (IRR 2.47, 2.12 to 2.89) higher and for those with a BMI of 18.5-
23 IRR was 1.38 (1.23 to 1.54) compared to those with a BMI of 23-25. The risk then tended to 
increase only in those with BMI>30: 1.21, 0.98 to 1.50). For females, a BMI <18.5 was also 
strongly related with the risk of mortality but at a lower relative risk compared to that in males 
(IRR 1.60, 1.30 to 1.98) and the risk did not increase at higher levels of BMI (fig 1d). Of note, 
the follow-up data for females at BMI>30 was relatively small (about 8000 PYFU). 
Sensitivity analyses 
Supplementary Table-S1, http://links.lww.com/QAI/B162 shows IRRs from all models with 
BMI categorised using the deciles of the distribution. Results were similar for all outcomes: for 
all SNAEs (except diabetes), relative risk was highest in the lowest 10% of the BMI distribution 
(equivalent to BMI<19.5) and tended to increase from the tenth decile (equivalent of BMI>28.7). 
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Lagging the BMI by 2 years (instead of 1) or analysing ‘baseline’ BMI instead on time-updated 
BMI broadly showed similar results (data not shown). Finally, data on creatinine were not 
uniformly available for all participants. Adjustment for creatinine clearance for CVD and all-
cause mortality mildly attenuated IRRs for CVD but did not have any significant effect on the 
overall results or conclusions (data not shown). 
 
DISCUSSION 
In this longitudinal analysis of HIV-positive individuals enrolled in the DAD cohort, we found 
that the relationship between BMI and the risk of SNAEs including CVD, NADCs, ‘BMI-related 
NADCs’ and all-cause mortality was non-linear. In general, low BMI (<18.5, and also <23 in 
case of NADC and all-cause mortality in males) was associated with the higher risk of these 
SNAEs. Relative risk of SNAEs then only tended to increase again at BMI levels >30 which was 
most prominent for CVD, ‘BMI-related NADC’ and all-cause mortality in men. Finally, for 
diabetes, the risk increased in a linear fashion with increasing BMI, with relative risk nearly 3.5 
times at BMI>30 compared to BMI of 23-25. Categorising BMI according to deciles of the 
distribution confirmed similar findings and broadly agreed with our choice of clinical cut-offs. 
Results were also robust to lagging BMI by 2 years or analysing baseline BMI to further 
minimise reverse causality. 
Traditionally studies in HIV/AIDS examined BMI in the context of AIDS in the pre- or early 
ART era. Only a few recent studies have carefully examined BMI in the context of SNAEs in 
treated HIV-positive individuals. A study by Koethe et al with about 1200 HIV-positive 
participants in a single site cohort found that low BMI (<20) was associated with a higher risk of 
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composite of SNAEs, while intermediate BMI of around 25-30 and high BMI >30 was 
associated with lower or similar risk to BMI of 20-25.9 Our findings are broadly similar to those 
noted in the latter study; however, we did find elevated risk of several SNAEs at BMI>30. Of 
note, the relative risk at BMI>30 was small for most outcomes (ranging from 1.31 for CVD, 1.21 
for all-cause mortality in men) but was nearly two- fold higher for ‘BMI-related NADCs’. 
However, the study by Koethe et al only used BMI at baseline and did not have consistent data 
on smoking.  
The finding that low BMI is associated with higher risk of death is consistent across studies even 
in the general population.5 In a large individual-data meta-analysis of nearly 4 million adults, 
BMI <18.5 was associated with about 1.8 fold higher risk of mortality in men compared to BMI 
of 22.5-25 after adjusting for smoking (corresponding IRR in our study was 2.47).5 This 
association was previously thought to be due to reverse causality (i.e. the disease affecting the 
BMI). However, in our study, this association remained even after ensuring the BMI precedes 
the outcome by at least 1 or 2 years. Also smoking tends to be inversely related to BMI and is an 
important confounder to account for.15,16 While our models adjusted for time-updated smoking, 
residual confounding from smoking cannot be ruled out. We also found higher risk of CVD in 
individuals with low BMI. Besides possible residual confounding by smoking, it is possible that 
people with low BMI get less aggressive disease prevention interventions compared to those 
with higher BMI. Our study did not collect health prevention or health behaviour data to be able 
to analyse this possibility. For the cancer outcomes, it is possible that weight loss starts several 
years prior to the diagnosis which may explain their associations with lower BMI.   
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Findings on intermediate to high BMI and all-cause mortality in the general population have 
tended to vary, although many of these studies did not adjust for smoking or had a shorter 
follow-up.5,17 However, the large meta-analysis described above, after adjustment for smoking, 
found relative risk of all-cause mortality in males to be around 1 for BMI 25 to 30, but increasing 
to 1.47 with BMI of 30-35, and to 2.0 in those with BMI>40.5 In our study, risk of all-cause 
mortality in males was high even at BMI of 18.5-23 (considered near optimal in general 
population), and then only tended to increase at BMI >30 in males. Relative to those with a low 
BMI, individuals with intermediate BMI tend to have greater muscle mass, exercise capacity and 
greater fat stores which may help in surviving stressful disease situations and confer survival 
advantage in sicker patients.18 Indeed, a large systematic review of patients with coronary artery 
disease at baseline found that mortality was highest at BMI <18.5 and lowest for those deemed 
‘overweight/mildly obese’ (BMI ranges 25-30) and the risk increasing only at severely high BMI 
>35.19 A cohort study evaluating mortality after coronary bypass graft surgery found similar 
results.20 
We found that the BMI above 30 was associated with elevated risk of CVD which attenuated 
after adjustment for blood pressure, lipids and incident diabetes. Increasing BMI was also 
associated with increasing risk of diabetes. This suggests that high BMI could be a useful initial 
screening tool in individuals where detailed CVD risk factors are not known. Finally, though 
high BMI >30 was not associated with the higher risk of NADCs, it was associated with higher 
risk of ‘BMI-related NADCs’ with overall relative risk of around 2 (compared to BMI 23-25). In 
the general population, obesity is increasingly being recognised as the risk factor for several 
cancers, with reasonably consistent evidence for oesophagus, pancreas, colon and rectum, breast, 
endometrium, kidney, thyroid and gallbladder cancers.4,11 While the relative risk for specific 
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cancers varies, we did not have enough follow-up data to examine effect of BMI on specific 
cancers.  
Our study benefitted from data on HIV-positive females. Findings were similar for females for 
all outcomes, except for all-cause mortality where the magnitude of risk at extremes of BMI in 
females was lower compared to males. A US cohort study on HIV-infected women found low 
BMI as predictor of mortality but not the high BMI (>25 or >30).21 Our findings on females in 
our cohort was consistent with this study. Of note, person-year data on females was limited 
especially at extremes of BMI which may have limited our power to analyse events in this sub-
group. 
The strengths of our study include a large heterogeneous cohort, with well-validated (through 
established protocols) outcomes and longitudinally measured BMI. Also, we were able to 
account for several key confounders in a time-updated fashion, including smoking and ART 
agents. Our study does have some limitations however. First, we did not have enough follow-up 
data and events at very high BMI levels (e.g. >35), which would have helped us further clarify 
the risks associated with severe obesity. Also, data on other risk factors such as health behaviors 
(e.g. diet/exercise) or preventive interventions (e.g. cancer screening) were not available. 
Moreover, other anthropometric measures such as waist:hip ratio which could be more accurate 
or supplement BMI were not available in this study. Also, even though our study designed 
ensured BMI measurements preceded diagnoses of SNAEs temporally, role of reverse causality 
cannot completely be ruled out given chronic nature of SNAEs. Finally, we could not perform a 
direct comparison between HIV-positive and negative individuals to better understand how BMI 
interacts with HIV or ART or population demographics and behaviour in determining outcomes.  
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In summary, we found that low BMI (≤18.5, and in some cases 18.5-23) was associated with 
high risk of several individual SNAEs as well as all-cause mortality. The relative risk of SNAEs 
and mortality did not increase at intermediate/moderately high BMI (around 23-30) and only 
tended to increase at BMI >30. These findings suggest that BMI of 25-30, thought to be 
‘overweight/mildly obese’ in general population may in fact confer some survival advantage in 
HIV-positive individuals. Also, these findings seem to suggest that obesity at BMI>30 is likely 
harmful in the long-term even in HIV-positive individuals. Future studies should assess how 
short-term and long-term changes in BMI relate to the risk of SNAEs. Ultimately, whether 
change in BMI or weight gain or loss interventions (depending on current BMI) would actually 
improve outcomes in this population will need trials on carefully designed behavioral and 
nutritional interventions. 
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Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
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Russia: (A Panteleev), O Panteleev, St Petersburg AIDS Centre, St Peterburg; A Yakovlev, 
Medical Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod Centre for AIDS, 
Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E 
Kuzovatova, Nizhny Novgorod Scientific and Research Institute of Epidemiology and 
Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E Borodulina, E 
Vdoushkina, Samara State Medical University, Samara. 
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.  
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.  
Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S Moreno, J. 
M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I 
Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA 
Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-
Gasteiz.  
Sweden:  (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital, Stockholm; A 
Blaxhult, Venhälsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, 
Malmö. 
Switzerland: (A Scherrer), R Weber, University Hospital Zurich; M Cavassini, University 
Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, University Hospital Bern; 
M Battegay, University Hospital Basel; P Schmid, Cantonal Hospital St. Gallen. 
Ukraine:  A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, Crimean 
Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and 
Control CTR, Lviv. 
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United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospital, London; 
AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, 
A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); C 
Orkin, Royal London Hospital, London; J Weber, G Scullard, Imperial College School of 
Medicine at St. Mary's, London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, 
Western General Hospital, Edinburgh. 
The following centers have previously contributed data to EuroSIDA: 
Infectious Diseases Hospital, Sofia, Bulgaria 
Hôpital de la Croix Rousse, Lyon, France 
Hôpital de la Pitié-Salpétière, Paris, France 
Unité INSERM, Bordeaux, France 
Hôpital Edouard Herriot, Lyon, France 
Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany 
1st I.K.A Hospital of Athens, Athens, Greece 
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy 
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy 
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy 
Dérer Hospital, Bratislava, Slovakia 
Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain 
AC
CE
PT
ED
Copyright  2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
29 
 
Kiev Centre for AIDS, Kiev, Ukraine 
Luhansk State Medical University, Luhansk, Ukraine 
Odessa Region AIDS Center, Odessa, Ukraine                                                                                                                                              
HivBivus (Sweden): 
Central coordination: L. Morfeldt, G. Thulin, A. Sundström. 
Participating physicians (city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson (Stockholm); L. 
Flamholc, C. Håkangård (Malmö). 
The ICONA Foundation (Italy): 
BOARD OF DIRECTORS 
A d’Arminio Monforte (President), A Antinori, A Castagna, F Castelli, R Cauda, G Di Perri, M 
Galli, R Iardino, G Ippolito, GC Marchetti, CF Perno, F von Schloesser, P Viale  
SCIENTIFIC SECRETARY 
A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E 
Girardi, S Lo Caputo, C Mussini, M Puoti 
STEERING COMMITTEE  
M Andreoni, A Ammassari, A Antinori, C Balotta, A Bandera, P Bonfanti, S Bonora, M Borderi, 
A Calcagno, L Calza, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, A Cingolani, P 
Cinque, A Cozzi-Lepri, A d’Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, 
A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo, G 
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Marchetti, S Marcotullio, L Monno, C Mussini, S Nozza, M Puoti, E Quiros Roldan, R Rossotti, 
S Rusconi, MM Santoro, A Saracino, M Zaccarelli. 
STATISTICAL AND MONITORING TEAM 
A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli 
BIOLOGICAL BANK INMI  
F Carletti, S Carrara, A Di Caro, S Graziano, F Petrone, G Prota, S Quartu, S Truffa 
PARTICIPATING PHYSICIANS AND CENTERS 
Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, C Santoro (Bari); 
F  Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelli, C 
Minardi, E Quiros Roldan (Brescia); T Quirino, C Abeli (Busto Arsizio); PE  Manconi, P Piano 
(Cagliari); B Cacopardo, B Celesia (Catania);  J Vecchiet, K Falasca (Chieti); A Pan, S 
Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); F Mazzotta, F Vichi (Firenze); G 
Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello (Genova); C Mastroianni, V Belvisi 
(Latina); P Bonfanti, I Caramma (Lecco); A Chiodera, P Milini (Macerata); A d’Arminio 
Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, G Marchetti, MC Moioli, R 
Piolini, AL Ridolfo, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); A 
Gori, G Lapadula (Monza); N Abrescia, A Chirianni, G Borgia, R Orlando, G Bonadies, F Di 
Martino, I Gentile, L Maddaloni (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, C 
Colomba (Palermo); F Baldelli, E Schiaroli (Perugia);  G  Parruti, F Sozio (Pescara); G Magnani, 
MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, V Vullo, R 
Acinapura, G Baldin, M Capozzi, S Cicalini, A Cingolani, L Fontanelli Sulekova, G Iaiani, A 
Latini, I Mastrorosa, MM Plazzi, S Savinelli, A Vergori (Roma); M Cecchetto, F Viviani 
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(Rovigo); G Madeddu, P Bagella (Sassari); A De Luca, B Rossetti (Siena);  A Franco, R Fontana 
Del Vecchio (Siracusa); D Francisci, C Di Giuli (Terni); P Caramello, G Di Perri, S Bonora, GC 
Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza) 
G Starnini, A Ialungo(Viterbo). 
Nice HIV Cohort (France):  
Central coordination: C. Pradier*, E. Fontas, K. Dollet, C. Caissotti.  
Participating physicians: P. Dellamonica, E. Bernard, J. Courjon, E. Cua, F. De Salvador-
Guillouet, J.Durant, C. Etienne, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost,S. Pillet , 
B. Prouvost-Keller, P. Pugliese, V. Rio, K. Risso, P.M. Roger. 
SHCS (Swiss HIV Cohort Study, Switzerland): 
The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals,15 
affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/180-health-care-
providers). 
Members of the Swiss HIV Cohort Study : 
Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, 
Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical 
and Laboratory Committee), Fux CA, Günthard HF (President of the SHCS), Haerry D (deputy 
of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser 
O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, 
Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni P, Rauch A (Chairman of the 
Scientific Board), Rudin C (Chairman of the Mother & Child Substudy), Scherrer AU (Head of 
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Data Centre), Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber 
R*, Yerly S. 
Funding 
Data on Adverse Events (D:A:D) Study:The D:A:D study was supported by a grant [grant 
number DNRF126] from the Danish National Research Foundation (CHIP & PERSIMUNE); the 
Highly Active Antiretroviral Therapy Oversight Committee (HAARTOC), a collaborative 
committee with representation from academic institutions, the European Agency for the 
Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient 
community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: 
AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare,  Merck & Co Inc. and 
Janssen Pharmaceuticals. Supported also by  a grant from the Dutch Ministry of Health, Welfare 
and Sport through the Center for Infectious Disease Control of the National Institute for Public 
Health and the Environment to Stiching HIV Monitoring (ATHENA); by a grant from the 
Agence nationale de recherches sur le sida et les hépatites virales [ANRS, Action Coordonnée 
no.7, Cohortes] to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is 
funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for 
AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of 
Health’s National Institute of Allergy and Infectious Diseases (NIAID) [grant number U01-
AI069907] and by unconditional grants from  Merck Sharp & Dohme; Gilead Sciences; Bristol-
Myers Squibb; Boehringer Ingelheim; Janssen-Cilag; ViiV Healthcare. The Kirby Institute is 
funded by The Australian Government Department of Health and Ageing, and is affiliated with 
the Faculty of Medicine, The University of New South Wales; by grants from the Fondo de 
Investigación Sanitaria [grant number FIS 99/0887] and Fundación para la Investigación y la 
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Prevención del SIDA en Espanã [grant number FIPSE 3171/00], to the Barcelona Antiretroviral 
Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, 
National Institutes of Health [grants number 5U01AI042170-10, 5U01AI046362-03], to the 
Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA);  by primary 
funding provided by the European Union’s Seventh Framework Programme for research, 
technological development and demonstration under EuroCoord grant agreement n˚ 260694 and 
unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., 
GlaxoSmithKline LLC, (the participation of centres from Switzerland is supported by The Swiss 
National Science Foundation (Grant 108787)) to the EuroSIDA study; by unrestricted 
educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, 
Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); 
and financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss 
National Science Foundation (grant #148522) and by the SHCS research foundation. 
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Fig-1: Latest BMI (lagged by 1 year) and the risk of SNAEs.  
Footnote: All models adjusted for sex, race, mode of HIV transmission, clinical cohort, calendar 
year and time-updated age, smoking and CD4 count. Additional adjustments are as follows: Fig-
1a: CVD: Model A additionally adjusted for being currently on abacavir, cumulative years on 
NRTIs and PIs. Model B: As model A plus additionally adjusted for time-updated (lagged by 1 
year) diabetes, total, HDL and LDL cholesterol, systolic and diastolic blood pressure. Fig 1b: 
Models for diabetes adjusted for HCV infection and following time-updated (lagged by 1 year) 
variables: cumulative years of stavudine use, triglycerides, and HDL cholesterol. Fig 1c and Fig 
1d: Models for cancer and all-cause mortality adjusted for hepatitis B or C co-infection. P for 
interaction between gender and BMI: <0.001 for all-cause mortality. BMI category of 23-25 was 
the reference category in all models.  
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Table-1: Baseline characteristics by baseline BMI category 
Note: BP= blood pressure, CVD= cardiovascular disease, HDL= high-density lipoprotein. Note: At baseline, mode of transmission was unknown in 7.7%;  smoking status was 
unknown in 20%; Hepatitis B and C status was unknown in  12% and 16% respectively; total cholesterol was missing in 7.8%, HDL cholesterol was missing in 31% and SBP was 
missing in 20% individuals. 
 
  
  BMI (kg/m
2
) category at baseline 
  <18.5 18.5-23 23-25 25-27.5 27.5-30 >30 Overall 
N (%) 1929 (4.7) 17640 (42.9) 9283 (22.6) 6998 (17.0) 2910 (7.1) 2389 (5.8) 41149 
Age in years (mean) (SD) 38.8 (9.8) 39.3 (9.3) 40.9 (9.8) 41.8 (9.9) 41.7 (10.2) 41.5 (10.3) 40.4 (9.7) 
Male (%) 55.1 72 79.6 80.3 73.1 56.2 73.5 
Infected with HIV through sex between 
men (%) 30.9 46.1 50.5 48.3 38.1 25.9 45 
Infected with HIV through Injecting drug 
use (%) 24.9 17.1 13.4 11.2 9.9 9.9 14.7 
Race- white (%) 47.6 52.5 51.2 50.2 45.9 39.4 50.5 
Current smoker (%) 52.3 46 38.3 33.4 28.1 24.7 39.9 
Family history of CVD (%) 6.6 6.7 7.1 7.2 5.7 7 6.8 
CD4 count/mm
3
 (median) (IQR) 
354 (205-535) 406 (269-600) 420 (284-610) 415 (277-601) 427 (290-614) 
420 (283-
635) 410 (273-635) 
Log10 HIV RNA (copies/mL) (median) 
(IQR) 2.1 (1.7-3.9) 1.9 (1.7-3.8) 1.9 (1.7-3.7) 1.8 (1.7-3.7) 1.8 (1.7-3.6)  2 (1.7-3.8) 1.9 (1.7-3.8) 
Hepatitis C coinfection (%) 29 21.7 18.1 14.9 13 12.5 18.9 
Hepatitis B coinfection (%) 5.9 5.7 5.4 5.3 5.1 4.3 5.5 
Total cholesterol mmol/L (mean) (SD) 4.7 (1.3) 4.9 (1.3) 5 (1.4) 5.1 (1.3) 5.2 (1.5) 5.1 (1.3) 4.9 (1.4) 
HDL mmol/L (mean) (SD) 1.3 (0.5) 1.25 (0.5) 1.19 (0.4) 1.17 (0.4) 1.18 (0.5) 1.18 (0.4) 1.22 (0.4) 
Systolic BP (mean) (SD) 115 (14.8) 120 (14.1) 124 (14.4) 126 (14.9) 128 (15.8) 129 (6.4) 123 (15.0) 
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Table-2: Number and incidence rates (95% CI) per 1000 PYFU of events by latest BMI category 
Note: Table shows N (incidence rates per 1000 PYFU [95% confidence interval]). BMI-cancers are cancers previously shown to be strongly associated with BMI in multiple general 
population studies (see text for details). All-cause mortality rates shown separately by gender because in regression models there was a significant interaction by gender 
(P<0.001 for interaction term). PYFU= person years of follow-up. 
  Latest BMI (kg/m
2
) category  
Events <18.5 18.5-23 23-25 25-27.5 27.5-30 >30 Overall 
CVD 97 (6.7 [5.5-8.2]) 578 (4.8 [4.4-5.2]) 298(4.6 [4.0-5.1]) 
242(4.8 [4.2-
5.4]) 
96(4.3 [3.5-5.3]) 87(4.9 [3.9-6.0]) 
1398 (4.8 [4.6-
5.1]) 
Diabetes 33 (2.3[1.6-3.2]) 248 (2.0[1.8-2.3]) 253 (4.0[3.4-4.4]) 
280 (5.6[4.9-
6.3]) 
184 (8.5[7.3-
9.8]) 
209 (12.2[10.6-
13.9]) 
1207 (4.2[3.9-
4.4]) 
Non-AIDS defining 
cancers (NADCs) 95 (7.9[6.4-9.6]) 510 (5.1[4.7-5.6]) 223 (4.0[3.6-4.6]) 
167 (3.8[3.3-
4.5]) 82 (4.2[3.4-5.3]) 66 (4.2[3.2-5.3]) 
1143 (4.7[4.4-
5.0]) 
BMI-cancers 12 (1.0[0.5-1.7]) 75 (0.8[0.6-0.9]) 32 (0.6[0.4-0.8]) 31 (0.7[0.5-1.0]) 13 (0.7[0.3-1.2]) 21 (1.3[0.8-2.0]) 
184 (0.7[0.6-
0.9]) 
All-cause mortality in 
males 
260 (33.2 [29.3-
37.5]) 
1138 (13.0 [12.3-
13.8]) 443 (8.4 [7.6-9.2]) 
333 (8.1 [7.3-
9.0]) 
142 (8.7 [7.3-
10.2]) 
102 (10.0 [8.2-
12.2]) 
2418 (11.2 [10.8-
11.7]) 
All-cause mortality in 
females 
116 (16.8 [13.9-
20.2]) 256 (7.4[6.5-8.3]) 94 (7.2[5.8-8.8]) 66 (6.2[4.8-7.9]) 33 (5.4[3.7-7.5]) 42 (5.2[3.8-7.1]) 
607 (7.6[7.0-
8.3]) 
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